CoQ10 and memory tests

What a study of ubiquinol and cognitive tests in adults aged 60 and over showed.

Key points

  • In adults aged 60 and over, ubiquinol showed no convincing advantage over placebo in the overall memory test result over 90 days. This trial did not demonstrate a confirmed improvement in memory. [1] See the evidence 1
  • In the study of adults aged 60 and over, no advantage in information processing speed was found either. The result does not support an expectation of marked improvement in speed on similar tasks. [1] See the evidence 1

Practical guide

Check the conclusions and whether they apply to your situation.

Memory and information processing speed were assessed separately.

Key points

Why these conclusions

Test results

Adults aged 60 and over took 200 mg of ubiquinol daily or placebo for 90 days. No convincing advantage in the overall memory test result or information processing speed was found; certainty in each outcome is low. [1]

In adults aged 60 and over, ubiquinol showed no convincing advantage in overall memory test result over 90 days.

ParameterData
ResultIn adults aged 60 and over, ubiquinol showed no convincing advantage in overall memory test result over 90 days. Difference −0.09 (95% CI −0.32 to +0.13).
Participants111 adults aged 60 and over randomized; memory assessed in 54 receiving ubiquinol and 44 receiving placebo.
FormOral ubiquinol, a form of CoQ10
Dose200 mg/day
Dose basis200 mg/day
Comparatorplacebo
Duration90 days
Confidence2/4: Precision: Exact confidence intervals allow a small difference in either direction. Consistency: No grounds for a separate downgrade. Applicability to the specified group: The study tested the stated form, participant group and outcome. Possible publication bias: No specific data for a separate downgrade. Study methods: Noticeable losses and unequal analysis across groups.
Evidence base1 trial; outcome from the same participant group
Sources[1]

Ubiquinol showed no convincing advantage over placebo in information processing speed.

ParameterData
ResultUbiquinol showed no convincing advantage over placebo in information processing speed. −0.03 (95% CI −0.24 to +0.18).
Participants111 adults aged 60 and over allocated to groups; processing-speed outcome assessed in 48 receiving ubiquinol and 41 receiving placebo
FormOral ubiquinol
Dose200 mg/day
Dose basis200 mg/day
Comparatorplacebo
Duration90 days
Confidence2/4: Precision: Exact confidence intervals allow a small difference in either direction. Consistency: No grounds for a separate downgrade. Applicability to the specified group: The study tested the stated form, participant group and outcome. Possible publication bias: No specific data for a separate downgrade. Study methods: Noticeable losses and unequal analysis across groups.
Evidence base1 trial; outcome from the same participant group
Sources[1]

More details

How to interpret results

The results apply to the studied form, age group and two sets of tests. [1]

Sources

  1. Effect of Ubiquinol on Cognitive Function, Blood Pressure, Arterial Stiffness, and Biomarkers of Oxidative Stress and Inflammation in the Elderly: A Randomized Trial. https://doi.org/10.3390/antiox15070806

Methodology: Subpages evidence-led supplement pipeline v1

Ingredient overview: Ubidecarenone